1. Home
  2. NNNN vs LQDA Comparison

NNNN vs LQDA Comparison

Compare NNNN & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NNNN
  • LQDA
  • Stock Information
  • Founded
  • NNNN 2021
  • LQDA 2004
  • Country
  • NNNN Germany
  • LQDA United States
  • Employees
  • NNNN N/A
  • LQDA N/A
  • Industry
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NNNN Health Care
  • LQDA Health Care
  • Exchange
  • NNNN Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • NNNN 2.2B
  • LQDA 1.9B
  • IPO Year
  • NNNN 2025
  • LQDA 2018
  • Fundamental
  • Price
  • NNNN $28.10
  • LQDA $23.89
  • Analyst Decision
  • NNNN
  • LQDA Strong Buy
  • Analyst Count
  • NNNN 0
  • LQDA 9
  • Target Price
  • NNNN N/A
  • LQDA $32.67
  • AVG Volume (30 Days)
  • NNNN 82.0K
  • LQDA 2.9M
  • Earning Date
  • NNNN 10-23-2025
  • LQDA 11-12-2025
  • Dividend Yield
  • NNNN N/A
  • LQDA N/A
  • EPS Growth
  • NNNN N/A
  • LQDA N/A
  • EPS
  • NNNN 0.06
  • LQDA N/A
  • Revenue
  • NNNN $8,185,146.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • NNNN N/A
  • LQDA $405.58
  • Revenue Next Year
  • NNNN N/A
  • LQDA $373.93
  • P/E Ratio
  • NNNN $566.20
  • LQDA N/A
  • Revenue Growth
  • NNNN 21.95
  • LQDA 30.20
  • 52 Week Low
  • NNNN $5.18
  • LQDA $9.71
  • 52 Week High
  • NNNN $55.65
  • LQDA $29.94
  • Technical
  • Relative Strength Index (RSI)
  • NNNN 38.40
  • LQDA 49.51
  • Support Level
  • NNNN $28.13
  • LQDA $21.35
  • Resistance Level
  • NNNN $33.32
  • LQDA $25.12
  • Average True Range (ATR)
  • NNNN 5.89
  • LQDA 1.21
  • MACD
  • NNNN -0.54
  • LQDA 0.09
  • Stochastic Oscillator
  • NNNN 26.27
  • LQDA 65.53

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: